Comment on Pantalone et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care 2020;43:1910–1919

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

We were interested in the recent article from Pantalone et al. (1), who reported that 23.7% of 6,973 subjects with poorly controlled type 2 diabetes (HbA1c >9%) attained HbA1c below 8% within 1 year, based on the electronic health record

Read More Comment on Pantalone et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care 2020;43:1910–1919

Response to Comment on Pantalone et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care 2020;43:1910–1919

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

We would like to thank Larroumet et al. (1) for their interest in our article (2) and for sharing their institution’s significant experience (3). Certainly, admission to a specialized ward can durably improve the HbA1c control in patients with uncontrolled

Read More Response to Comment on Pantalone et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care 2020;43:1910–1919

Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

We read the article by Gan et al. (1) with great interest and appreciate their exemplary work. The authors have concluded that among the newer antidiabetes drugs of 24 weeks’ duration, sodium–glucose cotransporter 2 inhibitors (SGLT-2i) lower HbA1c better in

Read More Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957

Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

In the July issue, Zhou et al. (1) published a systematic review of studies on the cost-effectiveness of interventions for the prevention of type 2 diabetes. Based on the findings from 17 studies (or study arms), from a health system

Read More Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616

Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

We would like to thank Singh et al. (1) for their correspondence, which makes some important points regarding the prescribing of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in Asian patients with type 2 diabetes.We

Read More Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957

Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616

Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

We thank Sathish et al. (1) for their interest in our systematic review on the cost-effectiveness of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations (2). Sathish et al. provided additional evidence from India and

Read More Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616

Les masques, ça marche. Vraiment. On va vous montrer comment.

Les masques, ça marche. Vraiment. On va vous montrer comment.

“Il est devenu clair que les masques en tissu, même s’ils ne sont pas aussi efficaces que les FFP2, permettent quand même de réduire la transmission”, dit Linsey Marr, une experte en aérosolisation à l’université Virginia Tech. “Même si vous

Read More Les masques, ça marche. Vraiment. On va vous montrer comment.

Les masques, ça marche. Vraiment. On va vous montrer comment.

Les masques, ça marche. Vraiment. On va vous montrer comment.

“Il est devenu clair que les masques en tissu, même s’ils ne sont pas aussi efficaces que les FFP2, permettent quand même de réduire la transmission”, dit Linsey Marr, une experte en aérosolisation à l’université Virginia Tech. “Même si vous

Read More Les masques, ça marche. Vraiment. On va vous montrer comment.

Response to Comment on McIntyre and Moses The Diagnosis and Management of Gestational Diabetes Mellitus in the Context of the COVID-19 Pandemic. Diabetes Care 2020;43:1433–1434

Response to Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948–955

We thank Issa et al. (1) for their interest in our commentary (2) and for their data regarding the potential consequences of applying the Royal College of Obstetricians and Gynaecologists (RCOG) modified guidelines for gestational diabetes mellitus (GDM) diagnosis during

Read More Response to Comment on McIntyre and Moses The Diagnosis and Management of Gestational Diabetes Mellitus in the Context of the COVID-19 Pandemic. Diabetes Care 2020;43:1433–1434

Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948–955

Response to Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948–955

We read with interest the recent study by Kwon et al. (1) examining the long-term effects of metformin use on mortality and incident end-stage kidney disease among 10,426 patients with type 2 diabetic kidney disease. The authors report that metformin

Read More Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948–955